Physician profile
Howard Blumstein
NPI 1598751471
$55,792.42
in general payments reported to CMS, 2019-2025
20 companies · $19K in 2025
The $19K reported for 2025 was more than what 92% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,196 · 2020: $18K · 2021: $4,031 · 2022: $2,102 · 2023: $2,067 · 2024: $2,752 · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $22K · Food and Beverage: $2,248 · Travel and Lodging: $36.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $21,600.00 |
| Food and Beverage | $2,248.02 |
| Travel and Lodging | $36.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Rheumatology | $28,750.00 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $18,538.78 | 2022-2025 | Orencia |
| Amgen INC. | $2,529.42 | 2019-2025 | Krystexxa, Otezla, Otezla |
| Fresenius Kabi USA, LLC | $1,458.67 | 2023-2025 | Idacio |
| Ucb, INC. | $1,330.41 | 2019-2022 | |
| Abbvie INC. | $818.18 | 2019-2025 | Rinvoq, Skyrizi |
| Horizon Therapeutics Plc | $580.56 | 2019-2023 | Krystexxa |
| Glaxosmithkline, LLC. | $568.10 | 2019-2025 | Benlysta |
| Janssen Biotech, INC. | $493.69 | 2019-2024 | Tremfya, Simponi Aria, Remicade |
| Genentech USA, INC. | $327.44 | 2019-2023 | Actemra, Rituxan |
| Pfizer INC. | $111.72 | 2019-2025 | |
| Depuy Synthes Sales INC. | $60.23 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $50.22 | 2024 | Saphnelo |
| Kiniksa Pharmaceuticals International, Plc | $42.62 | 2024 | Arcalyst |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.59 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $35.36 | 2022 | |
| Zimmer Biomet Holdings, INC. | $24.26 | 2024 | Visco-3 Sodium Hyaluronate |
| Radius Health, INC. | $15.46 | 2019 | |
| Fidia Pharma USA INC. | $14.71 | 2023 | Hym/Hyn |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Blumstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.